Effect of PF-00734200 in Subjects With Type 2 Diabetes

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of 12-Week Administration Of PF-00734200 To Subjects With Type 2 Diabetes Mellitus And Insufficient Glycemic Control On Metformin Treatment

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00618007

Enrollment

289

Registered

2008-02-18

Start date

2008-02-29

Completion date

2008-08-31

Last updated

2011-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Type 2

Brief summary

To determine the effect of PF-00734200 on HbA1c in type 2 diabetic subjects receiving metformin

Interventions

DRUGPF-00734200 30 mg QD

30 mg QD

DRUGPF-00734200 20 mg QD

20 mg QD

DRUGPlacebo

Placebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

Men or women between 18-80 years of age with poorly controlled Type 2 diabetes

Exclusion criteria

Type 1 or secondary forms of diabetes Currently using insulin

Design outcomes

Primary

Measure	Time frame
HbA1c	12 weeks

Secondary

Measure	Time frame
Fasting Glucose	12 weeks
Fasting Insulin	12 weeks

Countries

Canada, Puerto Rico, South Korea, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026